Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept

Kaya, Faruk

doi:10.1016/j.jfo.2017.04.014

Cited by 15 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty‐eight eyes in Group 1 and 41 eyes in Group 2 were included in the study. Mean follow‐up time was 6.2 ± 1.9 () months in Group 1 and 6.8 ± 2.1 (5–28) months in Group 2. The mean age was 69.6 ± 9.4 (53–90) years in the naive group and 71.9 ± 8.7 (57–86) years in the resistant group.…”

Section: Resultsmentioning

confidence: 99%

“…They found that the mean SCT of treated eyes decreased from 268.1 ± 101.3 μm to 233.0 ± 99.7 μm in three months and 232.4 ± 99.6 μm in 12 months. Kaya showed that SCT decreased significantly after both intravitreal ranibizumab and aflibercept injections in patients with NV‐AMD. Mazaraki et al evaluated the change in choroidal thickness following a loading dose of three intravitreal injections.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Aflibercept therapy in eyes with neovascular age‐related macular degeneration and its effect on choroidal thickness

Ismayılov

Esen

Demircan

2019

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Background: The purpose of this study was to investigate changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) and subfoveal choroidal thickness (SCT) after intravitreal aflibercept injections for neovascular age-related macular degeneration (NV-AMD). Methods: Eighty-nine eyes (48 treatment naive, 41 resistant) were included in this prospective study. All patients were treated with three consecutive monthly injections then every two months as required. BCVA, CMT and SCT were recorded and compared within and between the two groups. Results: The mean increase in BCVA after injections was 0.18 AE 0.34 logMAR in the naive group (p = 0.01) and 0.092 AE 0.38 logMAR in the resistant group (p = 0.131). The mean decrease in CMT was 200.3 AE 216.1 μm in the naive group and 183.3 AE 203.4 μm in the resistant group (p < 0.001 for both). The mean decrease in SCT was 22.1 AE 62.0 μm in the naive group (p = 0.014). The mean change in SCT was 22.28 AE 74.05 μm in the resistant group; this was not statistically significant (p = 0.061). Conclusion: BCVA, CMT and SCT decreased significantly after intravitreal aflibercept injections in naive patients with NV-AMD. Despite anatomic success, functional improvement was not reached and SCT did not significantly decrease after intravitreal aflibercept injections in resistant patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Aflibercept therapy in eyes with neovascular age‐related macular degeneration and its effect on choroidal thickness

Ismayılov

Esen

Demircan

2019

Clinical and Experimental Optometry

View full text Add to dashboard Cite

show abstract

“…Choroidal atrophy was also independently associated with the number of anti-VEGF injections regardless of the drug used, and it was more pronounced in eyes treated with anti-VEGF therapy for nAMD than in the non-nAMD control eyes [31]. Similarly, Kaya found that SCT decreased significantly in eyes treated with ranibizumab or aflibercept at 1, 3 and 6 months, yet aflibercept-treated eyes showed a significant further reduction in SCT when compared to ranibizumab [69]. Kim et al noted a greater decrease in SCT in eyes treated with aflibercept than in eyes treated with ranibizumab.…”

Section: Subfoveal Choroidal Thicknessmentioning

confidence: 90%

A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II

2020

View full text Add to dashboard Cite

Introduction: To explore the potential link between macular atrophy (MA) of the retinal pigment epithelium (RPE) in patients with neovascular age-related macular degeneration (nAMD) and anti-vascular endothelial growth factor (anti-VEGF) treatment. Methods: Through a balanced overview of the field from a largely clinical perspective, we looked at available evidence on the topic of MA correlation with anti-VEGF therapy and examined possible risk factors for MA development in the context of nAMD treatment with anti-VEGF. Results: Links have been reported to connect both MA incidence and progression to treatment frequency and to the anti-VEGF drug type. Conclusions: All reports agree on the fact that de novo development of MA in anti-VEGFtreated eyes is frequent and multifactorial. Research data shows an expansion of atrophy during anti-VEGF treatment. There are mixed conclusions about the correlation of MA incidence or progression with treatment-related risk factors. It mostly appears that there is no straightforward link. More clinical research is still needed to further understand this association.

show abstract

“…There are recent studies where choroidal thickness change was evaluated using EDI (enhanced depth imaging) OCT, with a much shorter-term follow-up time or a lower number of participants [ 16 , 17 ] and studies where measurement of choroidal thickness was performed using Spectralis OCT, after only a loading dose of intravitreal injection treatment [ 18 ]. The current study is, to the best of our knowledge, the only prospective study with in which swept-source OCT imaging has been used to assess the impact of anti-VEGF treatment on central macular choroidal thickness in nAMD.…”

Section: Discussionmentioning

confidence: 99%

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

et al. 2020

View full text Add to dashboard Cite

Aims To report the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and reading performance (reading acuity and maximum reading speed (MRS) using the MNREAD test) between baseline and 24 months in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept injections. Methods A prospective, open-label, interventional non-randomised case series with 24 months’ duration. Patients were recruited to the study from medical retina clinics at Moorfields Eye Hospital. Intravitreal injections of 2.0 mg aflibercept in the study eye were administered using a fixed dosing regimen during the first year and a treat-and-extend treatment regimen during the second year of treatment. Results Fifty patients were enrolled with a mean age (SD) of 78.7 (7.6) years; a mean BCVA of 62.8 ETDRS letters; mean reading acuity of 0.52 logMAR; mean maximum reading speed (MRS) of 141.3 words per minute and a central macular thickness of 322.6 µm at baseline. The mean improvement in BCVA was 6.4 letters for the 44 patients (88%) for whom data was available at 2 years. The mean improvement in reading acuity was 0.13 logMAR with an improvement in MRS of 2.9 words per minute. The mean reduction in CRT from baseline was 104.8 µm. Conclusions Aflibercept treatment of nAMD using fixed dosing in year 1 and treat and extend in year 2 leads to improvements in reading ability, visual acuity and retinal morphology which were maintained to 2 years of treatment. Trial Registration ClinicalTrials.gov Identifier NCT02441816, the VITAL study. Electronic supplementary material The online version of this article (10.1007/s40123-020-00267-5) contains supplementary material, which is available to authorized users.

show abstract

Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept

Cited by 15 publications

References 28 publications

Aflibercept therapy in eyes with neovascular age‐related macular degeneration and its effect on choroidal thickness

Aflibercept therapy in eyes with neovascular age‐related macular degeneration and its effect on choroidal thickness

A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Contact Info

Product

Resources

About